ArticleEarly intervention in psychiatry2026
Screening Performance of the DSM-5 Level 1 Cross-Cutting Symptom Measure to Detect Psychiatric Comorbidity Among Youth: A Community-Based Study.
Article in Early intervention in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionDetection of psychiatric comorbidity is essential given its high burden and frequent under-recognition. The DSM-5 Level 1 Cross-Cutting Symptom Measure (DSM-XC) is a multidimensional screener designed to capture relevant psychopathological domains, yet its ability to detect comorbid conditions remains unclear. In this study, we evaluated the DSM-XC's capacity to screen additional psychiatric comorbidity in individuals with an existing psychiatric diagnosis.
methodsCross-sectional data from 796 individuals aged 22 years (60.8% female) from the 1993 Pelotas birth cohort in Brazil were analysed. Participants were included if they met criteria for at least one of seven psychiatric diagnoses based on structured clinical interviews. Screening accuracy metrics were calculated for targeted DSM-XC domains in identifying secondary diagnoses (e.g., depression domain for major depressive disorder [MDD]), using standard and Youden-optimized thresholds. Non-targeted performance assessments (e.g., anxiety domain for MDD) were also performed. Additionally, all 13 domains and the total score were evaluated for detecting any comorbidity.
resultsFor the targeted domain assessment, high sensitivity and negative predictive values were observed using original thresholds, supporting rule-out utility, but specificity and positive likelihood ratios were low. The application of optimized thresholds increased specificity, with positive likelihood ratios reaching ~2 across domains. Non-targeted domains frequently outperformed targeted domains. Good discrimination for detecting any comorbidity was achieved using the DSM-XC total score (AUC = 0.75), with a cutoff of ≥ 21 providing the best balance between sensitivity (0.71) and specificity (0.69) and acceptable likelihood ratios.
conclusionsDSM-XC domains are useful for excluding comorbidities but have limited confirmatory value. The total score provides a global indicator of comorbidity. These findings support the DSM-XC primarily as a rule-out transdiagnostic triage tool for improving comorbidity detection in community settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.